Production process analysis: a review of the device history record confirmed that the device was manufactured and tested according to relevant procedures, and shipped according to manufacturer's specifications.User (surgeon and patient) information analysis: patient (b)(6) index procedure was performed on (b)(6) 2019.On (b)(6) 2023 apifix was notified that patient (b)(6) is scheduled for revision surgery on (b)(6) 2023 due to the device reaching its maximum elongation and the patient's curve at 40°.According to the doctor, the girl grew in height and the implant has now reached its maximum elongation.On (b)(6) 2023 the revision procedure occurred, during which the mid-c 125 was replaced with a new mid-c 125.No report of patient harm/complications was received.Reoperation events are a known risk that was assessed and recorded by the product risk management file.The risk of curve progression has been assessed and found to be acceptable.The current rate for all relevant criteria (curve progression, insufficient curve correction, imbalance) is in line with the rate reported in the literature for this type of complication as described in the company's cer (clinical evaluation report).The risk has been quantified, characterized, and documented as acceptable within a full risk assessment.The explanted device is not being returned to manufacture for analysis.Apifix is closing this complaint at this time, but will continue to monitor this 'failure mode'; complaint trending will continue to monitor per post marketing surveillance procedure.If new relevant information is made available, apifix will update the complaint record and file a follow up medwatch report.
|